Tandem high-dose 131I-MIBG therapy supported by dosimetry in pediatric patients with relapsed-refractory high-risk neuroblastoma: the Bambino Gesu’ Children’s Hospital experience
Conclusion
High-dose 131I-MIBG therapy combined with chemotherapy represent a well-tolerated and effective modality of treatment in heavily pretreated patients affected by relapsed/refractory NBL. However, further studies, including a wider cohort of patients, are needed.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
More News: Brain | Chemotherapy | Children | Neuroblastoma | Neurology | Nuclear Medicine | Pediatrics | Stem Cell Therapy | Stem Cells | Study